Sanofi's mRNA Covid-19 vaccine candidate not ready this year, CEO says

PARIS (Reuters) - A COVID-19 vaccine candidate developed by Sanofi and U.S.

group Translate Bio "will not be ready this year," the French drugmaker's chief executive told Le Journal du Dimanche newspaper. Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer/BioNTech and Moderna --, are expected to start this quarter. In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of.....

This article is no longer available in our repository.

There could be multiple reasons for this.